Ji Hyun Kim retweeted
Thrilled to co-author the Phase I study of FRฮฑ-targeting ADC Sofe-M in high-grade ovarian cancer, out now in @Annals_Oncology
๐ 50.5% ORR across FRฮฑ levels
& 58.8% at 3 mg/kg
Supporting Phase 3 #FRAmework01
๐ Free Share Link:
authors.elsevier.com/c/1o5CVโฆ
@gyncsm
๐จ New lecture in #colorectal surgery: โAlternatives to ostomy to protect very low colorectal anastomosesโ
๐ Watch the video on WebSurg: irc.ad/rIpm
Ji Hyun Kim retweeted
Many young women with breast and gyn cancers go into menopause overnight from treatment: ovarian suppression, tamoxifen or an AI, oophorectomy, pelvic radiation, chemotherapy. Hot flashes, no sleep, painful sex. Some stop the pill that protects them from recurrence.
What we can offer:
-- Hormone therapy: not a blanket no. It can be reasonable for some survivors; but after HR+ breast cancer it is generally avoided.
-- #Elinzanetant (Lynkuet): nonhormonal NK1/NK3 blocker, FDA approved for menopausal hot flashes. 120 mg at bedtime, LFTs at baseline and 3 months, check CYP3A4 interactions. Reduced hot flashes on endocrine therapy in OASIS-4; in the US that use is still under FDA review.
-- Venlafaxine or gabapentin: older, effective options.
-- Vaginal dryness: moisturizers and lubricants first.
Ask about it every visit.
Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer | New England Journal of Medicine nejm.org/doi/10.1056/NEJMoa2โฆ
Ji Hyun Kim retweeted
Deintensification trials in ICI should be in homogeneous population and based upon good biological and pharmacological rational. Excellent discussion by @DrJNaidoo @dr_yakupergun @myESMO #esmo26
Ji Hyun Kim retweeted
Conclusion in One line . Trial is negative for OS . And this approach should be used only in dMMR pts . #DUO-E @myESMO #esmo26 @OncBrothers @OncoAlert
Ji Hyun Kim retweeted
Can dMMR Endometrial Cancer Go Chemo-Free in the First Line?
Can dMMR endometrial cancer go chemo-free in 1L?
KEYNOTE-C93: pembrolizumab monotherapy improved PFS vs carboplatinโpaclitaxel; OS is still immature.
Magnitude of benefit & toxicity await LBA12.
@GynCancerMD @myESMO @GOG
#ESMO26 #GynOnc
Ji Hyun Kim retweeted
Iโm so sick of reviewers using ChatGPT to review papers. Itโs atrocious having to respond to the same garbage from all 3 reviewers where each comment requests 5 new analyses. Just donโt agree to review papers if itโs too much work ๐คทโโ๏ธ
Even if you used AI to review my paper- at least ensure the asks are genuine and then choose the most pertinent/relevant comments to include in your review? Is that too much work?
Iโm sure journal editors recognize that this is a real problem but canโt do much to rectify this issue.
Ji Hyun Kim retweeted
6,000๋ฒ ๋๋ฅธ ์์ ์์ฅ์ด ์๋ค
๋๋ ์ ๋ ์์ด์ ๊ฐ์ด์ ์๊ฐ๋ฝ ๋ ๊ฐ๋ก ๋๋ฅธ๋ค.
์ด๋ฅธ์ฒ๋ผ ์๋ฐ๋ฅ์ ํฌ๊ฐค ์๋ฆฌ๊ฐ ์๋ค.
1๋ถ์ 100๋ฒ์ด ๋๋๋ค. 2๋ถ๋ง๋ค ์ฌ๋์ด ๋ฐ๋๋ค.
60๋ถ์ด๋ฉด 6,000๋ฒ์ด ๋๋๋ค.
์์ ๋ผ๋ ์๋ฌด๋ ํํ์ง ์์ ์๊ฐ์ ํ์ฐธ ์ง๋์์ผ ์์ ๋ฉ์ท๋ค.
์์ด๋ ๋ ๋ฌ๋คโฆ
๋์ด ๋ง๋ฅด๊ธฐ ์ ์ ํ์ฌ 2๋ช
์ด ๋ค์ด์๋ค.
๋ณดํธ์๊ฐ ๊ทธ ์๋ฆฌ์์ ๊ฒฝ์ฐฐ์ ๋ถ๋ ๋ ๊ฒ์ด๋ค.
๋ค๋ฐ๋ผ ๊ณผํ์์ฌ๋ 3๋ช
์ด ์นด๋ฉ๋ผ๋ฅผ ๋ค๊ณ ๋ค์ด์๋ค.
77์ผ ๋ค์๋ 8๋ช
์ด ์๋ค.
๊ทธ๋ ์์ฌ๋ ๋ค๋ฅธ ์์ด์ ์จ๊ธธ์ ๊ฒจ์ฐ ํ์ ๋๊ณ ์ฒ๋ฐฉ์ ๋ฃ๋ ์ฐธ์ด์๋ค๊ณ ํ๋ค.
์์ฌ๋ ๋๋ง ์๋ค๋ ๋ง์ ์ค๋๋ ๋
ธ๋๋ค.
๋ ๋ณด๊ณ ์๋ ๊ฐ๋ค๋ ๋ง์ ๊ทธ ํ๋ ด์ด๋ค.
๋๋ง ์๋ ์ฌ๋์ด ์
์ด ๋น ๋ฅธ ๊ฒ์ ๋ง๋ค.
๊ทธ๋ฐ๋ฐ ์
์ด ๋น ๋ฅธ ์์ 60๋ถ์ ๊ฐ์ง ์๋๋ค.
30๋ถ์ด๋ฉด ์
์ด ๋๋๋ค. 60๋ถ์ ์
์ด ์๋๋ผ ๋ฏธ๋ จ์ด๋ค.
๋ฏธ๋ จ์ ๋์ด ๋์ง ์๋๋ค.
๋๋ง ์๋ค๋ ์์ด ๋๊ณผ ๊ฐ์ฅ ๋จผ 60๋ถ์ ๋ณด๋๊ณ ,
๊ทธ 60๋ถ์ ๋ณด๋ธ ๋ฐฉ์ ์์ฅ์ด ์๋ค.
๋ค์ ์์ด๋ 60๋ถ์ ๋ฐ์๊น?
์์ ๊ฑฐ์ง๋ง์ ๋ชป ํ๋ค. ๊ทธ๋ฌ๋ ์๋ ๋ฐฐ์ด๋ค.
๊ทธ๋ณด๋ค ๋จผ์ ๋ฌธ์ด ๋ซํ์ง๋ ๋ชจ๋ฅธ๋คโฆ
์์์๊ธ์ผํฐ ๊ฐํ์ ๋ด๋ฆฌ์๋ ๋ง์ด ํํ์์ ๋์๋ค.
6,000๋ฒ์ ์
์ ์๋ค.
ํ์ง๋ง ์ค์ง ์์ ์์ ์
์๊ฐ ์๋ค.
์ถ์ธํ ์์ฌ๋ ์์ฌ๋ฅผ ๊ทธ๋ง๋ ์ฌ๋์ด๋ค
๋ ์ ๋ฒ๊ณ ์ถ์ธํ๋ ค๊ณ ๊ณต๋ถ๋ง ํ ์ธ๊ฐ๋ค์ด๋ผ๋ ๋ง์ด ๋จ์ด์ง๊ณ ํฐ ๊ฐ์ด๋ค์ ์ผ๊ตด์ด ๊ตณ๋๋ค.
๋๋ ๊ทธ ์ผ๊ตด๋ค์๊ฒ์ ๋ค๋ฅธ ๊ฒ์ ๋ณธ๋ค.
์ด๋ฅธ๋ค ๋ง์ ์ ์ผ ์ ๋ค์ ์์ด๋ค์ด๋ค.
๊ณต๋ถํ๋ผ๋๊น ํ๊ณ , ์ํ๋ฉด ์๋์ ๊ฐ๋ผ๋๊น ๊ฐ๋ค.
๊ทธ ๊ฐ์ด์ ํ์ ์์ ์๋์ ์ผ ๋๊ณ ๊ธฐ๋ค๋ฆฌ๋ ๋ถ๋ชจ๋ค์ด ์
ํ ์ท์ด๋ค. ๊ณต๋ถ๋ง ํ ๊ฒ์ด ์ฃ๋ผ๋ฉด ๊ณต๋ฒ์ด ๋๋ฌด ๋ง๋ค.
์ถ์ธ๋ผ๋ ๋ง์ ๋ ์ด์ํ๋ค.
์ถ์ธ๋ ํ๋ ์ผ์ ๋๊ณ ๋ ๋์ ์๋ฆฌ๋ก ์ฎ๊ฒจ ๊ฐ๋ ๊ฒ์ธ๋ฐ, ์์ฌ๋ 30๋
์ด ์ง๋๋ ์ฒซ๋ ๊ทธ ์๋ฆฌ์์ ๊ฐ์ ์ผ์ ํ๋ค. ์ถ์ธํ ์์ฌ๋ ๋๊ฐ ์์ฌ๋ฅผ ๊ทธ๋ง๋ ์ฌ๋์ด๋ค.
๋ ์ชฝ์ ๋ ์ฌ๋ฏธ์๋ค.
์ด ๋๋ผ๋ง์์ ๋ ์๊ธฐ๋ ๋์ ์ข๋ ์๊ฐ์ ์์ฅ์ด ๋งก๊ณ ์ค๋ฆฌ ์๊ธฐ๋ ์์ฌ๊ฐ ๋งก๋๋ค. ๋ถ์
์ด ๊น๋ํ๋ค.
๋์ ๋ ๋ฒ๊ณ ์ถ์ ๋ง์์ ์ฒด์จ ๊ฐ์์
๋๊ตฌ์๊ฒ๋ ์๊ณ ์์ผ๋ฉด ํฐ์ผ ๋๋ค.
์ธ์์ ์์ฌ์๊ฒ๋ ์ ๋
์ฒด์จ๊ณ๋ฅผ ๋ค์ด๋๊ณ ์ด์ด ์๋ค๊ณ ํ๋ค. ๋๋ 30๋
์งธ ๋ฏธ์ด์ด๋ค. ๊ทธ ๋์ ์ค๋๋ ์ง๋ฃ์ค์ ์๋ค.
Ji Hyun Kim retweeted
Highly recommend reading these three papers in advance!
Also subscribe to our monthly newsletter here- oncologybg.com/newsletters/
Are you heading to #ESMO26 in Madrid? Donโt forget to attend the ESMO-MCBS special session on Friday afternoon! @oncology_bg will talk on how to read a clinical trial! cslide.ctimeetingtech.com/esโฆ
๐ด Mobilisation des lycรฉens :
"Je ne veux pas รชtre reprรฉsentant de quoi que ce soit, moi je suis un produit des rรฉseaux sociaux, j'en suis conscient. Dรจs que la vibe des blocus disparaitra, je disparaitrai avec", affirme Elwan dans #LaGrandeConfrontation
Ji Hyun Kim retweeted
๐article in press: Efficacy of cryotherapy in preventing taxane-induced neuropathy: The CryoPac randomised controlled trial
doi.org/10.1016/j.annonc.202โฆ
Ji Hyun Kim retweeted
๐จ NEW ASCO 2026 GUIDELINE: Recurrent Ovarian Cancer
A practical treatment algorithm worth saving ๐
PLATINUM-SENSITIVE recurrence
โ Platinum doublet remains backbone:
โข Carboplatin + PLD
โข Carboplatin + paclitaxel
โข Carboplatin + gemcitabine
โ Bevacizumab may be added, followed by maintenance bevacizumab
โ Do NOT add trabectedin to PLD
PLATINUM-RESISTANT / REFRACTORY
โญ FRฮฑ-high: Mirvetuximab soravtansine = strong recommendation
Other options:
โข PLD
โข Paclitaxel
โข Bevacizumab + chemotherapy
โข Relacorilant + nab-paclitaxel
โข Gemcitabine
SURGERY
Secondary cytoreduction is not routinely recommended based on current evidence, but may be discussed when complete gross resection is highly achievable.
HIPEC
Evidence remains insufficient for a routine recommendation.
Key message:
Recurrent ovarian cancer is becoming increasingly biomarker-driven and patient-selected, especially in platinum-resistant disease.
@ASCO @JCO_ASCO @OncoAlert
#OvarianCancer #GynOnc #Oncology
๐งฌ KEYLYNK-001 (Lancet Oncol 2026)
Does adding pembrolizumab to chemo + olaparib help first-line BRCA non-mutated ovarian cancer?
doi:10.1016/S1470-2045(26)00223-8
1
1
191
๐ Progression-free survival:
Pembro+ola 22.1 vs 14.6 mo
HR 0.68, p<0.0001
Pembro alone (CPSโฅ10): HR 0.95
Overall survival: HR 1.04
1
40
Ji Hyun Kim retweeted
๋
ผ๋ฌธ PDF๋ง ์์ด๊ณ , ์ฝ๊ณ ๋์๋ ๋จ๋ ๊ฒ ์๋ค๋ฉด ์ด 3๊ฐ ์ ์ฅํด๋๋ฉด ๋จ.
๊ด๋ จ ๋
ผ๋ฌธ ์ฐพ๊ธฐ โ ๋งํ ๋ด์ฉ ์ง๋ฌธํ๊ธฐ โ ๊ทผ๊ฑฐ์ ๋ฉ๋ชจ ๋จ๊ธฐ๊ธฐ.
๊ด์ฌ ๋ถ์ผ๋ฅผ ์ฒ์ ๊ณต๋ถํ๊ฑฐ๋ ์ฐ๊ตฌ ์ฃผ์ ๋ฅผ ํ์ํ ๋ ์ฐ๋ ์กฐํฉ์.
1. ResearchRabbit
๋
ผ๋ฌธ ํ๋๋ฅผ ๊ธฐ์ค์ผ๋ก ๋น์ทํ ์ฐ๊ตฌ์ ์๋ค๋ก ์ด์ด์ง๋ ์ฐ๊ตฌ๋ฅผ ์ฐพ์๋ณด๊ธฐ.
โ์ด ๋
ผ๋ฌธ ๋ค์์๋ ๋ญ ์ฝ์ด์ผ ํ์ง?โ ์ถ์ ๋ ์ฐ๊ธฐ ์ข์.
๊ธฐ๋ณธ ๊ฒ์๊ณผ ๋
ผ๋ฌธ ๋ชจ์ ๊ธฐ๋ฅ์ ๋ฌด๋ฃ์.
researchrabbit.ai/
2. Gemini Notebook โ ๊ธฐ์กด NotebookLM
๋
ผ๋ฌธ PDF๋ฅผ ๋ฃ๊ณ ์ฐ๊ตฌ ๋ฌธ์ ยท๋ฐฉ๋ฒยท๊ฒฐ๊ณผ๋ฅผ ์ง๋ฌธํ๊ธฐ.
์ดํด๊ฐ ์ ๋๋ ๋ถ๋ถ์ ์ขํ ๋ฌป๊ณ , ๋ต๋ณ์ ๋ถ์ ์ถ์ฒ๋ก ์๋ฌธ์ ํ์ธํ ๋ ์ฐ๋ฉด ๋จ.
notebook.google/
3. Zotero
๋
ผ๋ฌธ๊ณผ ๋ฉ๋ชจ๋ฅผ ํจ๊ป ๋ณด๊ดํ๊ณ , ๋ฐ์ค ์น ๋ถ๋ถ์ ์ถ์ฒ๊ฐ ์ฐ๊ฒฐ๋ ๋
ธํธ๋ก ๋ชจ์ผ๊ธฐ.
๋์ค์ โ์ด ์ค๋ช
์ด ์ด๋ ๋
ผ๋ฌธ์ ์์์ง?โ๋ฅผ ๋ค์ ์ฐพ์ ๋ ์ฐ๊ธฐ ์ข์.
zotero.org/
๋
ผ๋ฌธ ์ฐพ๊ธฐ โ ์ง๋ฌธํ๋ฉฐ ์ฝ๊ธฐ โ ์๋ฌธ ๊ทผ๊ฑฐ์ ๋ฉ๋ชจ ์ ์ฅํ๊ธฐ.
์ฒ์์๋ ๋
ผ๋ฌธ ํ ํธ์์ โ๋ฌด์จ ๋ฌธ์ ๋ฅผ ํ์๋์ง, ์ด๋ป๊ฒ ํ์๋์ง, ์ด๋๊น์ง ํ์ธํ๋์งโ๋ง ๋จ๊ฒจ๋ณด๋ฉด ๋จ.
AI ์์ฝ์ ๋ชจ์ผ๋ ๊ฒ๋ณด๋ค, ๋ด๊ฐ ์ค๋ช
ํ ์ ์๋ ๋ด์ฉ๊ณผ ๋ค์ ํ์ธํ ๊ทผ๊ฑฐ๋ฅผ ํจ๊ป ๋จ๊ธฐ๋ ๋ฐ ์ฐ๋ฉด ์ข์.
Ji Hyun Kim retweeted
In advanced high-grade serous #OvarianCancer, early assessment of chemosensitivity may help identify patients most likely to benefit from response-adapted treatment intensification before maintenance therapy. ja.ma/4jxZys4
Ji Hyun Kim retweeted
Historically, medical research has relied heavily on male participants, with findings often generalized to women and children.
If womenโs health is discussed at all, itโs largely framed around reproduction.
This special issue of Science highlights the research that is seeking to close the critical gaps in womenโs health. Learn more: scim.ag/4hy8ACT

ALT Women make up more than half the population, but most of what we know about womenโs biology comes from extrapolation of studies in men. This has been changing in recent years, and this special issue highlights some of the progress in understanding the biological basis of sex differences in health and disease and medical issues relevant to womenโs health across different stages of life. Illustration: Chiara Vercesi




































